NCT07204171View on ClinicalTrials.gov

Phase 1 Study of Oral MG001

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Safety and Tolerability in Healthy Subjects
Interventions
DRUG

mitragynine

Mu opioid receptor partial agonist

DRUG

Placebo

Each of the four dose groups of n=8 participants will be assigned to active drug or placebo in the ration 6:2.

Trial Locations (1)

66212

Altasciences Clinical Kansas, Overland Park

All Listed Sponsors
collaborator

Altasciences Clinical Kansas, Inc.

UNKNOWN

collaborator

Technical Resources International, Inc. (TRI)

UNKNOWN

lead

National Institute on Drug Abuse (NIDA)

NIH

NCT07204171 - Phase 1 Study of Oral MG001 | Biotech Hunter | Biotech Hunter